An 18-year-old Nanaimo BMX rider has received an outpouring of support after suffering a spinal injury in New Zealand. Ryley ...
Robotics is a fast-growing market, projected to expand from $94.54 billion in 2024 to surpass $372.59 billion by 2034. Industrial robots are currently leading this growth. Today, more than 3.4 ...
The FDA just approved a new type of pain medication, and it's a non-opioid called suzetrigine that stops body pain at its ...
Suzetrigine, to be sold under the brand name Journavx, is the first new type of pain medicine approved by the FDA in more ...
The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment ...
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side effects.
The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...
The Food and Drug Administration announced the approval of a new non-opioid pain medication this week, marking the first time ...
The FDA has approved a new type of painkiller that doesn't come with the risks of addiction and overdose associated with opioids.
Patients seeking an opioid-free way to handle pain experienced in the short-term will soon have a new option.
The US Food and Drug Administration has approved Journavx, also known as suzetrigine 50 milligram oral tablets—a first-in-class non-opioid analgesic—to treat moderate to severe acute pain in adults.